Allergy biotech Aimmune in $145M Nestlé Health equity investment
Nestlé Health Science has invested $145 million into Aimmune ($AIMT), as it continues to expand into the biotech sphere and looks to bolster its food-allergy programs. The equity investment from Nestlé Health will help Aimmune shore up work on CODIT ...
Nestle Pays $145 Million for Stake in Biotech Firm AimmuneBloomberg
Nestlé invests $145 million in food allergy therapeutics firm AimmuneThe Pharma Letter (registration)
Nestlé Invests in Aimmune to Fund Research for Food Allergy TreatmentsDrug Discovery & Development
all 14 news articles »
Wisconsin Energy Corp., Oracle Corp., and General Electric Co. may all see active trading after deals, or talk of deals.
Powered by WPeMatico